AVSU
American Century ETF Trust - Avantis Responsible U.S. Equity ETF

2
Loading...
Loading...
News
all
press releases
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.
Stocktwits·2d ago
News Placeholder
More News
News Placeholder
Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’
The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.
Stocktwits·7d ago
News Placeholder
RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite
Telsey Advisory Group stated that if an additional sector tariff on furniture is imposed, RH has the highest exposure within the home furnishings coverage group due to a high percentage of sales from furniture and limited sourcing in the U.S.
Stocktwits·14d ago
News Placeholder
Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened
The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.
Stocktwits·15d ago
News Placeholder
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.
Stocktwits·23d ago

Latest AVSU News

View

Advertisement|Remove ads.

Advertisement|Remove ads.